Receive clinical trial results for the Phase 3 dry eye chamber trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 13 Jun 2024
- Due
- 30 Sep 2024
- Delivered
- 8 Aug 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We anticipate receiving results from the clinical trial in the third quarter of 2024”
What we found
Evidence strength A What the grades mean
The company announced the results of the Phase 3 dry eye chamber trial on August 8, 2024, which is within the third quarter of 2024.
-
A Aldeyra Therapeutics, Inc. 10-Q filed 2025-05-14
“The chamber crossover trial, as announced on August 8, 2024, achieved the primary endpoint (P=0.004) of reducing patient-reported ocular discomfort in a dry eye chamber.” ✓ confirmed on the page
Market reaction: the shares moved +2.6% against the S&P 500 over the three sessions around the disclosure (13 May 2025 to 16 May 2025). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Receive
- Deliverable
- Phase 3 clinical trial results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-ALDX-003543 · Corrections policy